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Glutamine together with glucose is essential for body’s homeostasis. It is the most
abundant amino acid and is involved in many biosynthetic, regulatory and energy
production processes. Several membrane transporters which differ in transport modes,
ensure glutamine homeostasis by coordinating its absorption, reabsorption and delivery
to tissues. These transporters belong to different protein families, are redundant and
ubiquitous. Their classification, originally based on functional properties, has recently been
associated with the SLC nomenclature. Function of glutamine transporters is studied
in cells over-expressing the transporters or, more recently in proteoliposomes harboring
the proteins extracted from animal tissues or over-expressed in microorganisms. The
role of the glutamine transporters is linked to their transport modes and coupling with
Na+ and H+. Most transporters share specificity for other neutral or cationic amino
acids. Na+-dependent co-transporters efficiently accumulate glutamine while antiporters
regulate the pools of glutamine and other amino acids. The most acknowledged glutamine
transporters belong to the SLC1, 6, 7, and 38 families. The members involved in
the homeostasis are the co-transporters B0AT1 and the SNAT members 1, 2, 3, 5,
and 7; the antiporters ASCT2, LAT1 and 2. The last two are associated to the ancillary
CD98 protein. Some information on regulation of the glutamine transporters exist, which,
however, need to be deepened. No information at all is available on structures, besides
some homology models obtained using similar bacterial transporters as templates. Some
models of rat and human glutamine transporters highlight very similar structures between
the orthologs. Moreover the presence of glycosylation and/or phosphorylation sites
located at the extracellular or intracellular faces has been predicted. ASCT2 and LAT1 are
over-expressed in several cancers, thus representing potential targets for pharmacological
intervention.
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INTRODUCTION
The pivotal role of glutamine in cell metabolism of mammals is
well recognized. Besides glucose, glutamine represents a primary
nutrient for maintenance of body’s homeostasis (Bode, 2001;
Abbreviations: TCA, tricarboxylic acid cycle; MeAIB, methylaminoisobutyrate;
BCH, 2-aminobicyclo(2,2,1)heptane-2-carboxylic acid; SLC, Solute Carrier trans-
porters; mTOR, mammalian target of rapamycin; FXR, farnesoid X receptor;
RXR, 9-cis-retinoic acid receptor; IR-1, inverted repeat 1; EGF, epidermal growth
factor; PKC, protein kinase C; MEK, tyrosine/threonine kinase; IGF, insulin-
like growth factor; PI3K, phosphoinositide 3-kinase; SGK, serum/glucocorticoid
regulated kinase; PKB, protein kinase B; MCT, lactate membrane transporter;
ACE2, angiotensin-converting enzyme 2; APN, aminopeptidase N/CD13; CATs,
cationic amino acid transporters; LATs, light subunits of amino acid transporters;
HATs, heterodimeric amino acid transporters; TMS, trans-membrane domain;
IPTG, isopropyl β-D-1-thiogalactopyranoside; DHT, dihydrotestosterone; ERK1/2,
mitogen-activated protein kinase; APC, amino acid polyamine-organo cation fam-
ily; EAAT1, excitatory amino acid transporter SLC1A3; EAAT2, excitatory amino
acid transporter SLC1A2; PKA, protein kinase A; GLS1, glutaminase 1; OCTN,
organic cation transporter novel; SERT, serotonine transporter; RMSD, Root Mean
Square Deviation.
Newsholme et al., 2003; McGivan and Bungard, 2007). Therefore
glutamine plasmatic concentration must be regulated and kept
constant. Glutamine is the most abundant amino acid: the intra-
cellular concentration ranges from 2 to 20mM, while the extra-
cellular one ranges from 0.2 to 0.8mM (Bode, 2001; Newsholme
et al., 2003). It is involved in many cell processes, the most impor-
tant of which are depicted in Figure 1. Glutamine is precursor
for proteins, amino sugar, purines and pyrimidines synthesis in
different tissues; it is essential for acid-base buffering in kid-
ney, being the most important donor of NH3 excreted in urine
(Busque and Wagner, 2009; Verrey et al., 2009). Interestingly, in
kidney and liver the carbon skeleton of glutamine enters the TCA
cycle participating to gluconeogenesis. The amount of glucose
produced through this pathway accounts for 25% of the circu-
lating glucose which increases in case of diabetes (Stumvoll et al.,
1999; Curi et al., 2005; Daye and Wellen, 2012). Glutamine rep-
resents fuel also for intestine, where it plays the additional role
in maintaining gut integrity. Several reports show that glutamine
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FIGURE 1 | The glutamine roles in cell pathways. Schematic
representation of the cell processes involving glutamine. Proteins, protein
synthesis; Aminosugar, aminosugar synthesis; Nucleotides, purine and
pyrimidine synthesis; pH homeostasis, mainteinance of acid-base balance;
Gluconeogenesis, precursor synthesis; Energy, providing carbon atoms for
TCA; Urea, release of NH3 in liver for urea synthesis; Gln/Glu cycle and
GABA, neurotransmission regulation; Glutathione, GSH synthesis and
redox balance regulation; Insulin secretion, glucose concentration
regulation; Gene expression, gene expression regulation.
administration helps recovery of intestinal integrity from patho-
logical conditions (Ziegler et al., 2000). In liver glutamine pro-
vides nitrogen atoms for the urea cycle, a metabolic pathway
compartmentalized between cytosol and mitochondria (Indiveri
et al., 1994). In brain, besides a role as scavenger of NH3, glu-
tamine participates to the glutamine/glutamate cycle, in which
glutamine is synthesized from glutamate reabsorbed from synap-
tic cleft (Broer and Brookes, 2001; Bak et al., 2006; Conti and
Melone, 2006). Glutamine is involved in the maintenance of
redox potential balance in terms of GSH/GSSG ratio. GSH syn-
thesis needs glycine, cysteine and glutamate, the latter deriving
from glutamine through glutaminase action (Shanware et al.,
2011; Daye and Wellen, 2012); moreover, glutamine entering
the TCA cycle, gives rise to reducing equivalents, NADPH, used
to increase GSH/GSSG ratio (Curi et al., 2005). Glutamine is
linked to insulin secretion by pancreatic β–cells where it stim-
ulates glucose oxidation with consequent increase of ATP/ADP
ratio. This event induces membrane depolarization and results in
increase of the intracellular Ca2+ level and, thus, insulin release
(Newsholme et al., 2003). Lastly, an important role for glutamine
is the regulation of several genes involved in signal transduc-
tion, metabolism, cell proliferation, cell defense and repair (Curi
et al., 2005) and refs herein) (Figure 1). Taken together, these
information highlight that glutamine has both acute and chronic
effects on cell metabolism and functions. Therefore, glutamine
must be considered “essential” even though it can be synthesized
endogenously. Indeed, patients with critical illness (HIV infec-
tions, muscle disorders and side effects of chemotherapy) take
advantage of glutamine supplementation. On the contrary, some
concerns on glutamine-rich diet in healthy individual have been
recently raised. Thus, further studies are needed to clarify these
points (Holecek, 2013). The significance of glutamine for cell
metabolism is proven by its role also in pathological conditions:
cancer cells, in fact, have a special need for amino acids, such as
glutamine, arginine and leucine which are those mainly required
as reported in Section “Glutamine transporters in human pathol-
ogy.” From the depicted scenario it emerges that the processes of
glutamine absorption from diet, renal reabsorption and delivery
to different tissues are essential and must be well coordinated.
Therefore, different transport systems should work in a con-
certed manner to allow this special amino acid performing all its
functions.
GLUTAMINE TRANSPORTERS: FROM FUNCTIONAL TO
MOLECULAR CLASSIFICATION
Glutamine transport processes are guaranteed by a number of
membrane transporters which share specificity for glutamine but
show differences in transport modes. The pleiotropic role of
glutaminemay be the reason why glutamine transporters, belong-
ing to several protein families, are redundant and ubiquitous
(Figure 2). These proteins are, in general, specific for several neu-
tral amino acids, therefore their classification, as well as their
functional identification, were not unequivocal. The classifica-
tion of these transporters was originally based on functional
properties, such as substrate specificity, ion and pH dependence,
kinetics and regulatory properties. This original classification led
to cluster in “systems.” System A and System L were the first
to be so-defined indicating “alanine-preferring” and “leucine-
preferring,” respectively (Oxender and Christensen, 1963). The
systems included one or even more transporters, still not identi-
fied as specific proteins, due to obvious difficulties to discriminate
a single function in entire cells.
Over the years, a broad classification was adopted which differ-
entiated between Na+-dependent and Na+-independent systems
(Bode, 2001). Several transporters sharing the specificity for glu-
tamine were described on the basis of specificity toward other
amino acids, inhibitors and modes of transport such as System
N which exhibits narrow specificity to glutamine, histidine and
asparagine (Schioth et al., 2013), System ASC specific for alanine,
serine and cysteine and System B0 with broad specificity to neu-
tral amino acids. Among the Na+-dependent transporters, the
best described are the transporters belonging to Systems A and
N, the ASCT2 transporter which belongs to System ASC, B0AT1
belonging to system B0.
Among the Na+-independent transporters, LAT1 and LAT2
which belong to system L, are the best characterized. Some other
less known transporters have been described whose relationship
with glutamine homeostasis is, however, not unequivocal. These
minor transporters will be dealt with to some extent in the sec-
tions below. A further feature used to distinguish different trans-
porters was the high (such as systems N) or low (such as ASCT2)
tolerance toward the substitution of Na+ by Li+. However, in
2003 Mackenzie et al suggested that Li+ tolerance is not per se a
useful criterion to classify amino acid transporters, since in some
instance it depends on membrane potential and on the param-
eters used in experiments (Mackenzie et al., 2003). Moreover,
transporters can be characterized by the different specificity for
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FIGURE 2 | The glutamine transporter network. Interplay among epithelial
polarized cells (apical membrane is depicted as brush-border; basolateral
membrane is in contact with blood) and other cells. Glutamine transporters are
indicated in the figure with different colors. Arrows indicate glutamine fluxes
from (red) or toward (blue) blood or from lumen to epithelial cells (blue); black
arrows indicate sodium fluxes; gray arrows indicate other amino acid and
proton fluxes. Simplified cytosolic and mitochondrial pathways are depicted:
synthesis of glutamine (in brain and other tissues), TCA, glutamine entering in
TCA (intestine and kidney tubule), synthesis of glutamate from TCA
intermediate (brain and other tissue) or from glutamine (liver), Urea cycle (liver).
amino acids and sensitivity to inhibitors; for example, the Systems
A and L could be functionally identified by response to the amino
acid analogMeAIB and BCH, respectively. Even though inhibitors
allow to follow a transport reaction of a specific protein excluding
that of other transporters, in the case of amino acid transporters,
this criterion was not unequivocal due to the redundancy and the
broad specificity of the glutamine transporters in cell.
Upon the identification of genes coding for amino acid trans-
porters and the progress in wide genome sequencing, the classifi-
cation of the glutamine transporters should be revised taking into
account the sequence similarity and the presence of motifs corre-
sponding to specific protein families. The SLC nomenclature may
be helpful for a more structured clustering of the transporters.
Several reviews already refer to SLC based classification for amino
acid transporters (Mackenzie and Erickson, 2004; Hagglund et al.,
2011; Bodoy et al., 2013; El-Gebali et al., 2013; Fotiadis et al.,
2013; Kanai et al., 2013; Pramod et al., 2013; Rask-Andersen et al.,
2013).
Referring to SLC, the classification of glutamine transporters is
a little more complicated, since in some instances they are homol-
ogous to transporters for amino acids with different chemical
properties. For these reasons, due to some discrepancies among
similarity in function and similarity in amino acid sequences, the
functional classification does not match completely the sequence
similarity classification. SLC was previously used for the glu-
tamine transporters by McGivan and Bungard together with the
different names associated to the specific transporters (McGivan
and Bungard, 2007). Table 1 resumes the two classifications for
the glutamine transporters. The different modes of transport
displayed by these transporters determine their roles in the dif-
ferent tissues and in polarized membranes (Figure 2). Thus,
Na+-dependent symporters perform the function of efficiently
absorbing glutamine in epithelia using the electrochemical
gradient; this allows net accumulation of the amino acid against
transmembrane gradient. Antiporters perform the function of
regulating the balance between pools of glutamine and other
amino acids or protons in specific tissues such as the neuronal
subtypes; these transporters allow also glutamine efflux from spe-
cific tissues. Interaction of some of the glutamine transporters
with accessory proteins has been described. In the case of the glu-
tamine transporters LAT1 and LAT2, it seems that the accessory
proteins are part of the transport competent complex or at least
are important for stabilizing the protein into the plasma mem-
brane (Costa et al., 2013; Rosell et al., 2014). We expect increasing
evidences of interaction of the glutamine transporters with other
proteins for regulative purposes. Regulation of the glutamine
transporters is, indeed, essential for accomplishing its homeosta-
sis, also in response to variations of intracellular and extracellular
glutamine levels. However, relatively few information is available
on this topic, so far.
Function of the glutamine transporters has been initially
studied mainly in cell systems over-expressing the transporters.
Significant advancements to the knowledge of the glutamine
transporters derived from studies in artificial systems which give
the important advantage to exclude interferences ascribed to
other transporters and/or cell enzymes. In these systems, native
transporters extracted from model animals were firstly reconsti-
tuted (Oppedisano et al., 2004; Oppedisano and Indiveri, 2008).
The most promising approach is currently represented by the het-
erologous expression of the human isoforms of transporters in
microorganisms. So far, three glutamine transporters have been
successfully over- expressed in E. coli or in the yeast P. pastoris,
interestingly, all at the same time (Costa et al., 2013; Galluccio
et al., 2013; Pingitore et al., 2013), establishing the basic strategies
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Table 1 | The basic characteristics of the glutamine transporters.
Family Member System Aliases Mechanism Variant Regulator/ mode
SLC1 A5 ASC ASCT2, ATB0 Na+-glutamine/ neutral
amino acids antiport
Isoform1: NP_005619.1
Isoform 2: NP_001138616.1
Isoform 3: NP_001138617.1
Glutamine/protein expression
EGF/trafficking and activity
Insulin and IGF/activity
mTOR/protein expression
Leptin/trafficking and gene expression
pRb/protein expression
Aldosterone/protein expression
SLC6 A14 B(0,+) ATB0,+ 2Na+-1Cl−-glutamine
co-transport
(electrogenic)
NP_009162.1 EGF and GH/expression
A19 B or B0 B0AT1 Na+- glutamine
co-transport,
(electrogenic)
NP_001003841.1 collectrin (kidney), ACE2/trafficking
APN (intestine)/activity and trafficking
Leptin/trafficking and gene expression
potassium/activity
JAK2 (Janus kinase-2)/trafficking
PKB-Akt and SGK/trafficking
A15 B0AT2 Na+-glutamine
co-transport,
(electrogenic)
Isoform 1: NP_877499.1
Isoform 2: NP_060527.2
Isoform 3: NP_001139807.1
SLC7 A5 L LAT1 glutamine/ large neutral
amino acids antiport
NP_003477.4
XP_006721350.1*
XP_006721349.1*
4F2hc/trafficking c-Myc/protein
expression
EAA/protein expression
Glucose/up regulation Aldosterone
/protein expression
insulin/increases mRNA abundance
A8 LAT2 glutamine/ small neutral
amino acids antiport
Isoform 1: NP_036376.2
Isoform 2: NP_877392.1
Isoform 3: NP_001253965.1
Isoform 4: NP_001253966.1
4F2hc/trafficking
Aldosterone/protein expression
mTORC1/trafficking
DHT/protein expression
A6 y+LAT2 Na+ -glutamine /cationic
amino acids antiport
NP_001070253.1 4F2hc/ trafficking
SLC38 A1 A SNAT1, ATA1,
SAT1, NAT2
Na+-glutamine
cotransport
(electrogenic)
Isoform 1: NP_001265317.1
Isoform 2: NP_001265319.1
A2 SNAT2, ATA2,
SAT2, SA1
Na+-glutamine
cotransport
(electrogenic)
Isoform 1: NP_061849.2
Isoform 2:
XP_005269040.1*Isoform 3:
BAG57253.1*
DHT/activity
glucagon/expression
A3 N SNAT3, SN1,
NAT
Na+-
glutamine/H+antiport
(electroneutral)
NP_006832.1 Insulin/trafficking
PKC/trafficking
Manganese/degradation
A5 SNAT5, SN2 Na+-glutamine/H+
antiport
(electroneutral)
Isoform 1: NP_277053.2
Isoform 2: XP_005272752.1*
c-myc/expression
A7 SNAT7 Na+-
glutamine/H+antiport
(electroneutral)
Isoform 1: NP_060701.1
Isoform 2: XP_006721292.1*
The SLC and System classifications are reported; Mechanism of transport is described; variants reported in GeneBank are listed; known regulators and their effect
are indicated.
*Predicted protein.
(Figure 3) for further advancement of the knowledge on the
glutamine transporter function and structure.
In the following paragraphs an update is given on the
glutamine transporter knowledge concerning functional,
regulatory and structural advancements and relationships with
human health, respect to the last excellent comprehensive
reviews on the glutamine transporters (Bode, 2001; McGivan and
Bungard, 2007).
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FIGURE 3 | Work flow of heterologous over-expression of membrane
transporters. Schematic representation of screening of different
combination Plasmid/Cell strains (white spots): if the attempts with wild
type gene is not successful, codon bias strategy should be applied. Thus,
selection of the best plasmid/cell strain combination is performed (red spot)
with optimization of conditions for high yield expression. When this result is
achieved, purification procedures are applied to perform both structural and
functional studies. These strategies allow large scale screening of potential
drugs or xenobiotics.
SLC1A5: ASCT2
GENE AND TISSUE LOCALIZATION
SLC1A5, known as ASCT2, is a glutamine transporter belonging
to the SLC1 family which encompasses five high affinity glutamate
transporters (SLC1A1, SLC1A2, SLC1A3, SLC1A6, SLC1A7) and
two neutral amino acid transporters (SLC1A4 and SLC1A5). In
humans, the five glutamate transporters possess 44–55% amino
acid sequence identity with each other, whereas the two neutral
amino acid transporters exhibit 57% identity. The human isoform
of SLC1A5 gene, isolated in 1996 from human placenta (Kekuda
et al., 1996), is annotated on the chromosome 19q13.3. Three
different transcripts exist in GeneBank, deriving from different
translation start (Kanai et al., 2013); up to now the functional
and kinetic characterizations have been conducted only on the
first variant (NM_005628) constituted by 2873 nucleotides and 8
exons (Table 1). This transcript encodes a peptide of 541 amino
acids. The dbSNP database reports more than 400 SNPs both in
coding and non-coding region. Only the variant SLC1A5-P17A
(rs3027956) is associated with breast cancer (Savas et al., 2006).
SLC1A5 gene is expressed in several tissues: kidney, intestine,
brain, lung, skeletal muscle, placenta and pancreas (Kekuda et al.,
1996; Utsunomiya-Tate et al., 1996; Broer and Brookes, 2001;
Deitmer et al., 2003; Gliddon et al., 2009; Indiveri et al., 2014).
FUNCTION
The acronym ASCT2 stands for AlaSerCys Transporter 2, even
though the preferred substrate is glutamine. Indeed, the impor-
tance of ASCT2 for human health is linked to the ability to
mediate delivery of this amino acid. The transport mechanism
of this transporter has been widely studied in different experi-
mental models: cell systems (Torres-Zamorano et al., 1998) as
well as proteoliposomes reconstituted with the rat transporter
extracted from kidney (Oppedisano et al., 2004, 2007; Pingitore
et al., 2013).More recently, the human protein was over-expressed
in P. pastoris and reconstituted in fully active form in proteolipo-
somes (Pingitore et al., 2013). This gave a further advancement
to the knowledge of the human transporter. All the experimen-
tal approaches revealed similar basic properties of the transporter
which works as a strictly Na+-dependent obligatory antiporter
of neutral amino acids (Table 1). Na+ cannot be substituted by
Li+. Experiments conducted with radioactive substrates as well as
competition data confirmed that also alanine, threonine, serine,
leucine, valine, asparagine, methionine, isoleucine, tryptophan,
histidine, and phenylalanine are substrates of this transporter.
Glutamate, lysine, arginine, MeAIB and BCH are not transported.
By using proteoliposomes, important novelties on the human
ASCT2 substrate specificity have been revealed. In particular,
human ASCT2 showed an asymmetric specificity for amino acids.
Glutamine, serine, asparagine, and threonine are bi-directionally
transported while alanine, valine and methionine can be only
inwardly transported. The functional asymmetry was also con-
firmed by kinetic analysis: different Km values were measured
on the external and internal sides of proteoliposomes, 0.097 and
1.8mM, respectively (Pingitore et al., 2013). The Na+ex :amino
acidex stoichiometry of transport is 1:1. The electrical aspect of
the transport reaction is, however, not completely clarified: in
fact, the inwardly-directed transport of Na+ should evoke electri-
cal currents, leading to an electrogenic transport (Kekuda et al.,
1996, 1997; Torres-Zamorano et al., 1998). Some groups, on the
contrary, described an electroneutral transport (Utsunomiya-Tate
et al., 1996; Broer et al., 1999). Interestingly, anion conductance
activity has been described by electrophysiological measurements
(Grewer and Grabsch, 2004). Very recently, using computational
and experimental approaches a transport mechanism in which
more than one Na+ ion is involved in amino acid translocation
has been suggested. The study showed that even if the amino acid
exchange occurs in an electroneutral mode, the transport cycle
is indeed electrogenic due to the movement of Na+ ions across
membrane. However, the used experimental model did not allow
assay at the intracellular side (Zander et al., 2013). Thus, to gain
further insights in the electrical properties of this transporter,
a more appropriate model is needed, in which the intracellu-
lar environment might be better controlled; this would be useful
also for defining the overall catalytic mechanism which is still
underneath. The physiological role of hASCT2 has been exten-
sively investigated in different tissue. ASCT2 in brain contributes
to the glutamine-glutamate cycle (Figure 1) mediating the efflux
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of glutamine from astrocytes to recover the glutamate released
in synaptic cleft (Broer et al., 1999). The same cycle occurs in
placenta where glutamine enters the fetal liver to synthesize gluta-
mate, which is then used for fetus metabolism (Torres-Zamorano
et al., 1998). An evolutionary role has also been proposed for
the human ASCT2 isoform: a group of retroviruses used this
transporter as a receptor to infect human cells, giving rise to a
co-evolution phenomenon (Marin et al., 2003). Moreover, among
them, the human endogenous retroviruses (HERVs) have been
detected as transcripts and proteins in the central nervous system.
Associations among these retroviruses with syndromes includ-
ing multiple sclerosis (MS) and several psychiatric disorders have
been described. Binding of HERV proteins to ASCT-1 or -2 recep-
torsmight reduce the amino acid intake (Antony et al., 2011). One
of the most important signaling function reported for ASCT2
relies on the link with the mTOR pathway. mTOR is an highly
conserved Ser/Thr kinase that forms two complexes (mTORC1
and mTORC2) by interacting with several other proteins. mTOR
pathway integrates signals from five major routes: growth fac-
tors, stress, energy status, oxygen and amino acids. In particular,
leucine and arginine should be involved in activating mTOR.
However, the link with the amino acid signals is still underneath.
In this scenario, glutamine taken up by ASCT2 stimulates leucine
uptake by a parallel leucine/glutamine antiport catalyzed by LAT1
(Nicklin et al., 2009).
REGULATORY ASPECTS
Several data on regulation of ASCT2 expression is reported
both in physiological and pathological conditions, even though
the molecular mechanisms of regulation are mostly unknown
(Table 1). One of the first report dealing with this issue showed
that glutamine itself is able to regulate ASCT2 expression in
human hepatoma cells (Bungard and McGivan, 2004). In the
mentioned study, a region of 907 bp flanking the 5′ of ASCT2
gene has been cloned in the luciferase reporter system. In this
system, glutamine strongly induces the promoter activity possibly
via FXR/RXR dimer formation. This transcription factor complex
binds to an IR-1 repeat of 24 bp in the promoter region of ASCT2.
This has been further demonstrated by the site-directed muta-
genesis of the IR-1 region. Furthermore, it has been postulated
that the expression of FXR, which is linked to glucose availabil-
ity, may positively regulate glutamine (Bungard and McGivan,
2005). Soon after, other groups proposed that glutamine trans-
port through ASCT2 is stimulated by EGF signaling pathway
(Palmada et al., 2005; Avissar et al., 2008). This should involve
activation of PKC and protein kinase MEK. The uptake of amino
acid is also regulated by insulin and IGF, which activate a cas-
cade involving PI3K and the downstream targets SGK and PKB.
The regulation of ASCT2 is due to increase of its abundance in
plasma membrane even though ASCT2 does not harbor a canon-
ical consensus sequence for these kinases (Palmada et al., 2005).
This is in line with the observation that the transporter traffick-
ing is a PI3K-dependent phenomenon and that the transporter
stabilization in membrane is due to the GTPase Rho (Avissar
et al., 2008). The link of ASCT2 with mTOR pathway has been
suggested in 2007 by Fuchs et al.; the study showed that silenc-
ing ASCT2 in hepatoma cells causes reduction of mTOR activity,
leading to apoptosis (Fuchs et al., 2007). Rapamycin decreases
ASCT2 expression, indicating a reciprocal effect between this
transporter andmTOR activity. The phenomenon underlying this
mechanism is still underneath (Fuchs et al., 2007). Interestingly,
in 2005 a study by Xu et al, reported the isolation of a super-
complex constituted by LAT1/CD98, MCT/CD147 (lactate mem-
brane transporter) heterodimers and ASCT2, which would be
under regulation of AMPK and mTOR (Xu and Hemler, 2005).
This would fit with the need of simultaneously regulating such
transporters, which are fundamental for energetic metabolism,
particularly in cancers (Ganapathy et al., 2009). Down-regulation
of ASCT2 expression has been reported in intestine by the mul-
tifunction hormone leptin, which is involved in modulating the
activity of several transporters of energy rich molecules (Ducroc
et al., 2010). Lastly, the tumor suppressor pRb via E2F-3 tran-
scription factor has been shown to regulate ASCT2 expression
as well as other proteins involved in glutamine metabolism.
Interestingly, in cancer the constitutive pRb degradation leads to
continuous activation of E2F-3 and, then, enhanced expression of
ASCT2 (Reynolds et al., 2014).
STRUCTURAL ASPECTS
In spite of the different physiological roles in mammals, SLC1
familymembers share common structural features. The tridimen-
sional structure of the archeal homolog of the SLC1 family, Gltph
from P. horikoshii, was solved by X-ray crystallography (Yernool
et al., 2004). The structure of Gltph has a trimeric architecture
forming an aqueous cavity. In 2007 the same group solved the
structure in presence of substrate and of a competitive inhibitor
(Boudker et al., 2007), opening the possibility of docking analysis
with substrates and inhibitors. Each protomer is an independent
transport unit and is formed by eight transmembrane domains
and two hairpin loops (HP1 and HP2) which are thought to be
responsible of substrate translocation, being the mobile part of
the transporter (Boudker et al., 2007; Reyes et al., 2009).
The first homology model of rat ASCT2 has been constructed
in 2010 (Oppedisano et al., 2010), followed by others which
confirmed the putative structure of the glutamine transporter
(Albers et al., 2012; Zander et al., 2013). More recently the human
ortholog has been modeled (Pingitore et al., 2013). Homology
models of human and rat ASCT2 are shown in Figure 4. Despite
the 79% sequence identity between the two orthologous proteins,
a very low identity degree (14%) has been found in local stretches
(aa 200–229) as shown by themodel (Figure 4A). The localization
of this region is predicted in the vicinity of the substrate binding
site (Oppedisano et al., 2010). Two putative glycosylation sites are
reported in the homology model (N163, N212 for human and
N164, N215 for rat) which are conserved and exposed toward the
extracellular face, according with the proposed orientation of the
protein in membrane (Figure 4B).
Another relevant difference between the two orthologs is
the number of cysteines. 8 Cys residues are conserved in
both the proteins, while the rat isoform contains additional 8
Cys residues. Two of these residues (C207 and C210) form,
in the rat ASCT2, a CXXC metal binding motif missing in
the human isoform. Function/structure relationships studied in
proteoliposomes highlighted the importance of Cys residues in
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FIGURE 4 | Homology models of ASCT2 human and rat transporters.
The homology structural models of rat and human ASCT2 were obtained by
the Modeler 9.13 software (Sali and Blundell, 1993) using as template the
structure (PDB 1XFH) of the glutamate transporter homolog from
P. horikoshii (Glpth). To run the software, sequences were aligned by
ClustalX2 software with .pir output format. RMSD for model comparison
was calculated by Spdbv 4.1.0. Superposition of the rat and human
structural models was performed by VMD 1.9.1. (A) The human protein
(transparent) contains a variable loop in bleu, the rat one (purple) contains a
variable loop in red. The Cys residues of the CXXC metal binding motif
present only in the rat protein are highlighted in yellow. (B) The human
protein is in gray; the rat one is in bleu. Putative glycosylation sites of both
proteins are highlighted in red. Cysteine residues common to the two
orthologous proteins are highlighted in light green. Additional Cys residues
present only in rat protein are highlighted in yellow. N- and C- terminals of
rat and human proteins are nearly coincident and highlighted by single N
and C.
substrate translocation which is potently inhibited by specific
Cys reagents. Interestingly, ASCT2 harbors the two hairpins,
HP1 and HP2, which are important for substrate translocation
(Pingitore et al., 2013). This finding suggests that the transloca-
tion mechanism may be similar to that of Glpth, even though
ASCT2 works by an antiport mode of transport. Therefore,
additional constraints are needed for coupling substrate transport
in opposed directions.
SLC6A19: B0AT1
GENE AND TISSUE LOCALIZATION
SLC6A19 belongs to the SLC6 also called Na+-dependent neu-
rotransmitter transporter family in which only one out of 21
members is a well characterized glutamine transporter. Few other
members of the family recognize glutamine but with lower affin-
ity respect to other substrates (Verrey et al., 2005; Broer, 2006;
Pramod et al., 2013).
B0AT1 was identified and cloned from mouse cDNA library;
it shows all properties of the system previously defined as B0
(Broer et al., 2004). The transporter localization was found in
proximal tubules and intestinal microvillus. B0AT1 was then rec-
ognized as one of the major transporters of neutral amino acids in
these epithelia (Bohmer et al., 2005; Camargo et al., 2005; Broer
et al., 2011) (Figure 2). Also in humans, B0AT1 has been local-
ized in kidney and intestine. Lower, but significant expression has
also been found in skin, pancreas, prostate, stomach, liver (Kleta
et al., 2004; Seow et al., 2004). The genomic localization of the
mouse B0AT1 is on chromosome 13 in cytoband C1, syntenic to
human chromosome 5p15. The human gene is constituted by 12
exons. Two transcripts are reported in the data bases, but only
one (5174 bp) codes for a protein, while the other one (3337 bp)
undergoes nonsense mediated decay (Table 1).
FUNCTION
The function of mouse and human B0AT1 was initially studied in
oocytes. The transporter recognizes, besides glutamine, leucine,
cysteine, valine, isoleucine, methionine, phenylalanine, alanine,
serine, and asparagine as main substrates. Threonine, glycine,
proline, histidine, tyrosine, tryptophan and BCH showed also
some affinity for the transporter even though lower than glu-
tamine. While arginine, lysine, aspartate, glutamate and MeAIB
are not substrate. Half saturation constants of the mouse trans-
porter for glutamine, measured by different authors, range from
0.5mM to more than 3mM (Broer et al., 2004; Bohmer et al.,
2005). Km of the human transporter was reported to be 0.25mM
(Souba et al., 1992). However, the Km on the internal side of
the transporter could not be measured in oocytes. Transport cat-
alyzed by B0AT1 is well recognized to be electrogenic. An Hill
coefficient of 1.5 of the Na+ dependence suggests that either
two Na+ are co-transported with amino acids or that 1 Na+ is
co-transported and a seconds second ion binds to an allosteric
site (Broer et al., 2004). Further studies demonstrated a 1:1 sto-
ichiometry (Bohmer et al., 2005; Camargo et al., 2005). The
replacement of Na+ with Li+ is not tolerated. It was also sug-
gested that the transporter may provide pathways for Na+, H+,
and/or Cl− that are not thermodynamically coupled to the amino
acid transport indicating not saturable channel-like, as opposed
to carrier-mediated activity (Camargo et al., 2005). This phe-
nomenon is similar to that found for the mitochondrial carriers
but has not a physiological explanation (Tonazzi and Indiveri,
2003) and refs herein). Regarding the mechanism of transport,
either a random model was proposed (Bohmer et al., 2005) or an
ordered mechanism (Camargo et al., 2005) in which Na+ would
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follow substrate binding. The discrepancies among the different
studies are caused by differences in the experimental systems, by
the confounding presence of multiple transport systems and by
the complexity of the entire cell model (Camargo et al., 2005;
McGivan and Bungard, 2007; Oppedisano and Indiveri, 2008).
Significant clarification and advancement of the knowledge on
B0AT1 were provided by the more recent studies of the protein
extracted from rat kidney and inserted in proteoliposomes. In
this experimental model, the transporter was inserted right side
out respect to the cell orientation, thus giving the possibility to
gain information without the interferences but ascribable to the
cell context. Besides confirming some basic properties, such as
substrate, ion specificity and inhibitor sensitivity, the artificial
system gave information on the electrical nature of transport.
Electrogenicity originates from Na+ transport coupled to glu-
tamine, while Cl− has no influence on the electrogenic behavior.
Regulation by K+ was also found (see below). The half-saturation
constant for glutamine in proteoliposomes corresponded to a Km
measured in oocytes (Broer et al., 2004), i.e., 0.55mM. It was
clarified that the Na+-glutamine co-transport displays a 1:1 stoi-
chiometry and the transport mechanism is random simultaneous.
Interestingly, in proteoliposomes the intracellular Km could be
measured. Its value is 2.0mM indicating an asymmetric nature
of the transporter (Oppedisano and Indiveri, 2008; Oppedisano
et al., 2011). This data correlates well with the intracellular and
extracellular glutamine concentrations. Indeed the concentration
inside (about 2mM) is much higher than that outside the cell
(about 0.5mM) (Cynober, 2002). These data allows to speculate
that B0AT1 might, under some condition, catalyze also efflux of
glutamine (Oppedisano et al., 2011).
It can be concluded that the absorption of glutamine and other
neutral amino acids from intestine and reabsorption in kidney are
the primary functions of this transporter (Figure 2).
REGULATORY ASPECTS
Study on regulation of B0AT1 is at an advanced stage (Table 1).
The carboxypeptidase ACE2 and collectrin (non-peptidase
homolog of ACE2) have been described as key regulators of
intestinal and renal amino acid uptake (Fairweather et al., 2012).
Interestingly, collectrin was shown to specifically increase B0AT1
activity probably by enhancing its surface expression (Danilczyk
et al., 2006), not the intrinsic transport function. Proteoliposome
experiments demonstrated that collectrin has no essential role
in the catalysis of glutamine transport by B0AT1 (Oppedisano
et al., 2011). B0AT1 forms complexes with APN that increases
the affinity of the transporter for substrate up to 2.5-fold besides
increasing its surface expression (Fairweather et al., 2012). Leptin
modulates intestinal glutamine absorption through reduction of
B0AT1 trafficking to the plasma membrane (Ducroc et al., 2010).
Allosteric regulation by K+ has been described. K+ exerts a
biphasic modulation of the transporter interacting at the intra-
cellular site. Up to 50mM internal (intracellular) K+, transport
was stimulated while at higher K+ level it was inhibited. Since
the intracellular K+ level depends on ATP concentration, it can
be assessed that the nucleotide indirectly modulates the B0AT1
transporter activity. High ATP level, causing increase in K+,
would impair B0AT1 activity; lower ATP level will stimulate
B0AT1 (Oppedisano and Indiveri, 2008). This regulation is
opposed to the regulation by ATP found for the rat ASCT2.
The Janus Kinase 2 enhances the protein abundance in the cell
membrane (Bhavsar et al., 2011). PKB/Akt up-regulates SLC6A19
activity, which may foster amino acid uptake into PKB/Akt-
expressing epithelial and tumor cells (Bogatikov et al., 2012).
STRUCTURAL ASPECTS
According to protein similarity, B0AT1 displays LeuT fold. The
main properties influencing the substrate affinity are: the pres-
ence of the charged amino and carboxyl groups, L-configuration
(not D-) of the α-carbon, net neutral charge, size and, to a
lesser extent, hydrophobicity of the side-chains (Yamashita et al.,
2005). Uncharged amino acids are favored due to the predicted
interaction with a hydrophobic pocket. B0AT1 has similar sub-
strate specificity of LeuT with the exception of tryptophan, that
is weakly transported only by B0AT1 (Camargo et al., 2005;
Yamashita et al., 2005; Broer, 2006; O’mara et al., 2006). Another
difference is the co-transport of 2 Na+ in the case of LeuT, while
only 1 Na+ is co-transported by B0AT1. The role of the seconds
second Na+-binding site in B0AT1 remains unclear. The homol-
ogy model highlighted a structural asymmetry which correlates
with the function and explains the structural basis of the loss of
function of some mutants (Broer, 2008, 2009).
More recently, the dopamine transporter from Drosophila
melanogaster (PDB 4M48) has been crystallized and resolved at
2.95 Å (Penmatsa et al., 2013). The alignment of the B0AT1 with
the dopamine transporter has higher identity (33%) respect to the
LeuT transporter (18%), thus a more accurate modeling could
be obtained. The superposition of the rat and human structural
models (0.43 Å RMSD) shows that the two orthologs are very sim-
ilar (Figure 5), as expected from the 87% identity between the
human and rat protein and differently from ASCT2 (Figure 4A).
This similarity correlates well to the similar functional properties
of the two orthologs.
Database analysis (ExPASy PROSITE, http://www.expasy.ch/
prosite) of regulatory sites within the SLC6A19 amino acid
sequence predicted fiveN-glycosylation sites. Three (N158, N182,
N258) are reported in the homology model (Figure 5). The oth-
ers are not present since the region 332–377 containing these
residues cannot be modeled. According to the predicted orien-
tation, the glycosylation sites protrude toward the extracellular
side. The SLC6A19 sequence contains also a conserved intracellu-
lar consensus site (S100) for phosphorylation (Figure 5) which is
known to regulate a variety of channels and transporters (Bohmer
et al., 2010). Moreover, Figure 5 highlights the presence of two
conserved metal binding motifs in the middle of the transporter,
the CXXC (containing C200/C203) and the CXXXC motifs (con-
taining C45/C49). The first is located close to the membrane face,
far from the hypothetical substrate binding site; the seconds sec-
ond is in the core of the protein, closer to the substrate binding
pocket. The metal binding sites correlate well with the interac-
tion of heavy metals with the transporter, as described below
(Oppedisano et al., 2011).
SLC6A14: ATB0,+
SLC6A14 is the molecular counterpart of ATB0,+ belonging
to the system B0+. The hATB0,+ was the first cloned amino
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FIGURE 5 | Homology models of B0AT1 human and rat transporters.
The homology structural models of rat (gray) and human (blue) B0AT1 were
constructed as described in Figure 4 using as template the structure of
dopamine transporter from D. melanogaster (PDB 4M48). RMSD for model
comparison was calculated by Spdbv 4.1.0. Superposition of the rat and
human structural models was performed by VMD 1.9.1. Putative
glycosylation sites are highlighted in red; cysteine residues of the metal
binding motifs are highlighted in yellow; PKC phosphorylation site is
highlighted in green. N- and C- terminals of rat and human proteins are
nearly coincident and highlighted by single N and C.
acid transporter of system B0+ (Sloan and Mager, 1999). It is
expressed in colon, lung (Sloan et al., 2003), eye (Ganapathy
and Ganapathy, 2005) and mammary gland (Nakanishi et al.,
2001) (Table 1). This is a broad specificity transporter which rec-
ognizes glutamine with relatively low affinity (Bode, 2001) Km
0.6mM (Sloan and Mager, 1999) and other neutral as well as
cationic amino acids but also carnitine and carnitine derivatives.
Therefore, it can be considered a minor glutamine transporter.
Transport catalyzed by ATB0,+ is dependent on Na+ and Cl−
transmembrane gradients and is sensitive to membrane poten-
tial. 2 Na+ and 1 Cl− are involved in the transport (Nakanishi
et al., 2001). As found for ASCT2, ATB0,+ may be up-regulated
in cancer to meet the increasing demand of arginine (Gupta
et al., 2005, 2006), representing a potential target of cancer ther-
apy (Karunakaran et al., 2011). In this sense the selective blocker
methyl-DL-tryptophan (α-MT) or the BCH acid might represent
an important chemical scaffold for drug design (Sloan andMager,
1999).
SLC6A15: B0AT2
In 2006 it was demonstrated that the mouse v7-3 gene encodes
a transporter for neutral amino acids named B0AT2, due to
the high similarity with B0AT1 (Broer, 2006) (Table 1). The
results indicated that B0AT2 mediates Na+-dependent uptake
of leucine, isoleucine, valine, proline, methionine and with a
very low affinity glutamine. The transport is electrogenic with a
stoichiometry of 1 Na+:1 amino acid. Besides kidney, it is highly
expressed in cerebellum and brain. This localization indicates that
B0AT2 might be mainly involved in providing neurotransmitter
precursors to neurons. Nitrogen from leucine, in fact, is trans-
ferred to oxoglutarate to form glutamate; isoleucine, methionine
and valine can be metabolized to succynil-CoA for glutamate
biosynthesis. Thus, B0AT2 has marginal if any role in glutamine
homeostasis.
GLUTAMINE TRANSPORTERS OF THE SLC7 FAMILY
Important glutamine transporters belong to the SLC7 family
which accounts for 13 members divided in two subgroups: the
Cationic Amino acid Transporters (CATs) and the Light subunits
of Amino acid Transporters (LATs) of the Heterodimeric Amino
acid Transporters. Some general information will be given here to
highlight the peculiarity of the glutamine transporters belonging
to this family. HATs and CATs originate from a common ances-
tor with 12 trans-membrane domains (TMD) which duplicated
the last two TMD originating a 14 TMD structure (Verrey et al.,
2004; Hansen et al., 2011; Fotiadis et al., 2013). Only the HATs
group includes glutamine transporters. They mediate obligatory
antiport of a broad spectrum of substrates (Fotiadis et al., 2013).
HATs emerged in metazoan and represent one of the few exam-
ple of transporters composed by two different subunits. The Light
subunit of HATs, LATs, are known as glycoprotein-associated
amino acid transporters since they associate with heavy subunit
belonging to the SLC3 family via a conserved disulphide bridge
(Broer and Brookes, 2001; Wagner et al., 2001; Palacin and Kanai,
2004). This is a very small family of type II (with C-ter outside the
cells) membrane glycoproteins comprising SLC3A1 and SLC3A2,
named rBAT and 4F2hc, respectively. The main function of SLC3
proteins consists in routing the transporters to plasma membrane
forming the HAT complex. 4F2hc (heavy chain of the cell surface
antigen 4F2) is a multifunctional protein involved, besides trans-
port, in immuno system regulation, cell activation, growth and
adhesion (Palacin and Kanai, 2004; Cantor and Ginsberg, 2012;
Fotiadis et al., 2013). Furthermore, 4F2hc has been suggested to
play a role in integrin signaling and activation linking this protein
to human malignancies (Cantor and Ginsberg, 2012).
So far, six human light subunits have been identified as part-
ners of 4F2hc: LAT1, LAT2, y+LAT1, y+LAT2, asc1 and xCT all
belonging to the SLC7 family. This broad spectrum of interaction
justifies the ubiquitous expression of 4F2hc and the absence of
pathology linked to its complete loss which is, indeed, not com-
patible with life (Palacin and Kanai, 2004). Interestingly, an het-
erodimer complex formed with the glucose transporter GLUT1
has been reported, confirming the regulatory role of 4F2hc in gen-
eral transport mechanism (Ohno et al., 2011). As stated above,
the main interaction between LATs and heavy chain occurs via
disulphide formation; this, however, is not essential since muta-
tion of Cys does not abolish completely the presence of HATs in
membrane (Pfeiffer et al., 1998; Broer et al., 2001; Palacin and
Kanai, 2004; Franca et al., 2005; Rosell et al., 2014). The following
paragraph deals with the members of SLC7 involved in glutamine
disposition.
SLC7A5: LAT1
GENE AND TISSUE LOCALIZATION
The rat and human cDNAs encoding LAT1 protein have
been isolated and identified in 1998 and confirmed in 1999
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(Kanai et al., 1998; Prasad et al., 1999). The human gene has been
annotated in the chromosome 16q24.3 and is characterized by 10
exons. Three transcripts are reported on ensemble database, but
only one protein has been characterized. The longest (4537 bp)
codes for a protein of 507 amino acid. Other two isoforms of
241 and 334 amino acids are also predicted (Table 1), but without
evidence of transport activity. LAT1 is expressed in brain, ovary,
testis, placenta, spleen, colon, blood-brain barrier, fetal liver, acti-
vated lymphocytes, skeletal muscle, heart, lung, thymus, and
kidney (Kanai et al., 1998; Yoon et al., 2005). It is mainly local-
ized in the basolateral membranes of polarized epithelia (Verrey
et al., 2004; Fotiadis et al., 2013) (Figure 2).
FUNCTION
The first report describing hLAT1 activity (Prasad et al., 1999)
conducted in cell systems, revealed that LAT1 works as het-
erodimer. In several studies it has been assessed that LAT1 medi-
ates obligatory antiport of tryptophan, phenylalanine, leucine and
histidine with higher affinity (Km in humans ranging from 5 to
50μM) (Del Amo et al., 2008), glutamine and threonine with
lower affinity; alanine, proline and charged amino acids are not
recognized as substrates. The non-metabolizable analog BCH is
a transportable inhibitor of LAT1(Mastroberardino et al., 1998).
Interestingly, LAT1/4F2hc activity has been linked also to trans-
port of L-dopamine across the blood-brain barrier suggesting a
potential role of LAT1 in Parkinson’s disease (Kageyama et al.,
2000). Transport of thyroid hormones by LAT1 was also described
being important in neurological development (Kinne et al., 2011).
The covalent interaction between LAT1 and 4F2hc requires the
conserved C164 of human LAT1(C 165 in rat) and the conserved
C109 of human 4F2hc (C103 in rat) (Fort et al., 2007); either
the N-ter and the extracellular parts of 4F2hc are essential for
non-covalent interaction as demonstrated by experiments with
truncated mutants (Broer et al., 2001; Franca et al., 2005). The
transport mode has been described as Na+ and pH independent
(Table 1); this allows the relative concentration of large neu-
tral amino acids acting synergistically with other Na+-coupled
amino acid transporters, such as ASCT2 or unidirectional trans-
porters such as system A and N (Verrey, 2003; Del Amo et al.,
2008). LAT1 is also involved in regulation of signaling via mTOR,
which is responsible of cell growth and survival. This feature
shed light on the link between LAT1 and cancer (see Section
“Glutamine transporters in human pathology”). In OMIM data-
bank no pathologies are associated to inherited mutations of
LAT1 gene. Further information on unknown functional aspects
of human isoform of LAT1 will come from the availability of
the large scale over-expressed protein (Galluccio et al., 2013).
The achievement of such objective represents a great challenge
in protein field since amino acid transporters are known to be
toxic for bacteria (Miroux and Walker, 1996). hLAT1 represents,
in fact, the only case of a mammalian amino acid transporter
expressed in bacteria (Galluccio et al., 2013). A strategy previ-
ously used for OCTN subfamily was adopted for LAT1and 4F2hc
over-expression (Indiveri et al., 2013) (Figure 3). After screening
of plasmid and cell combinations, the pH6EX3 plasmid revealed
suitable for significant over-expression of the protein in E. coli
Rosetta DE3pLysS (Brizio et al., 2006; Torchetti et al., 2011).
Optimization of some parameters, such as temperature growth
and IPTG concentrations (Brizio et al., 2006) was performed and
followed by an affinity chromatography procedures (Galluccio
et al., 2013). The importance of this study relies on the unique
possibility of handling the human protein alone or in combi-
nation with the accessory protein 4F2hc (CD98) to characterize
function and kinetics.
SLC7A8: LAT2
GENE AND TISSUE LOCALIZATION
LAT2 gene from human and murine source was reported in 1999
by different groups (Pineda et al., 1999; Segawa et al., 1999). The
human gene is located in the chromosome 14q11.2 and encodes
for a protein of 535 amino acids with 12 putative TMDs. Human
LAT2 is mainly expressed in kidney, placenta, brain and at lower
extent in spleen, skeletal muscle, small intestine, lung (Pineda
et al., 1999; Fraga et al., 2005; Yoon et al., 2005; Fotiadis et al.,
2013) but also in prostate, ovaries, testis and fetal liver (Park
et al., 2005). As in the case of LAT1, LAT2 is mainly localized at
the basolateral membrane of polarized epithelia cells (Figure 2).
Alignment with hLAT1 shows 50% identity. Alternative tran-
scripts are annotated in GeneBank coding for three additional but
uncharacterized proteins (Table 1).
FUNCTION
In cell systems, it has been shown that only the co-expression of
hLAT2 and 4F2hc mediates uptake of neutral amino acids which
is highly trans-stimulated and Na+-independent. LAT2/4F2hc is
inhibited by the amino acid analog BCH as LAT1. The main dif-
ference with LAT1 is in the substrate choice: while LAT1 prefers
large neutral amino acids, LAT2 has a broader specificity mediat-
ing transport of small neutral amino acids such as alanine, glycine
and serine as well. Glutamine, for which LAT1 has low affinity, is
one of the main substrates of LAT2. However, LAT2 shows a gen-
eral lower affinity for substrates respect to LAT1, with Km ranging
in humans from 0.2 to 1mM (Del Amo et al., 2008). Differently
from LAT1, LAT2 is sensitive to more acidic pH (Christensen,
1990). The expression of LAT2 in brain, liver and skeletal muscle
suggests a role in mediating release of glutamine. An important
advance in LAT2 functional knowledge came from the success-
ful over-expression in P. pastoris of the heterodimer 4F2hc/LAT2
(Costa et al., 2013). Soon after the structural bases of the interac-
tion between the two subunits were revealed. This was confirmed
by reconstitution in proteoliposomes of the heterodimer. These
experiments indicated that 4F2hc is required for LAT2 stabi-
lization in membrane but not for modulating substrate affinity
(Rosell et al., 2014).
REGULATORY ASPECTS OF LAT1 AND LAT2 HETERODIMERS
The role played by LAT1 and LAT2 consists in equilibrating glu-
tamine and other amino acids pool into the cells, while their
net uptake derives from other transporters (Del Amo et al.,
2008). The study on the regulation of LAT1/4F2hc is of great
importance due to the key role played by this protein in several
human cancers (See Section “Glutamine transporters in human
pathology”). One of the first reports concerning this issue has
been conducted in lymphocytes, where the basal expression of
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LAT1/4F2hc has been found increased upon activation signals.
Studying the promoter regions of the two genes by 5′ RACE anal-
ysis and Run on assay suggested that control of LAT1 relates to
transcriptional activity not to the half-life of mRNA (Nii et al.,
2001). More recently, the LAT1 promoter has been analyzed in
human pancreatic cancer cells in which LAT1 plays key function
in promoting cell growth. The study revealed that LAT1 promoter
harbors a canonical binding sequence for the proto-oncogene
c-myc (Hayashi et al., 2012). This protein is an important tran-
scription factor whose expression is often altered in cancers since
it regulates expression of several genes controlling metabolism
and cell cycle (Daye andWellen, 2012). Silencing c-myc by siRNA
leads to down-regulation of LAT1 expression in prostate cancer
cells with subsequent decrease of proliferation, due to impair-
ment of neutral amino acids uptake. Mutations of c-myc binding
sequence on LAT1 promoter causes loss of responsiveness to
c-myc expression. However, the mechanism of control c-myc-
mediated may be more complicated since this protein can exert
both epigenetic control and can regulate mRNA translation effi-
ciency by microRNA expression (Hayashi et al., 2012). A recent
study described that ingestion of essential amino acids resulted
in humans in a transient increase of LAT1/4F2hc heterodimer;
this event has been linked to activation of mTORC1 signaling
and protein synthesis. The augmented expression might be an
adaptive response to long term amino acid availability and/or to
anabolic stimulus (Drummond et al., 2010). In line with this, a
recent finding shows that embryo of null mice for LAT1 gene has
a phenotype incompatible with life (Poncet et al., 2014). Glucose
deprivation, due to pathological conditions such ischemia, has
been also linked to up-regulation of LAT1 via cis-activation of
an E-box on its promoter region in retina (Matsuyama et al.,
2012). Low insulin concentration increases SLC7A5/LAT1 mRNA
abundance in an mTORC1-dependent manner in skeletal mus-
cle cells (Walker et al., 2014). Lastly, LAT1 protein expression
has been shown to be increased upon chronic treatment with
aldosterone (Amaral et al., 2008). Much less is known about
regulation of hLAT2 that responds like LAT1 to aldosterone
stimulus (Amaral et al., 2008). A regulation of LAT2/4F2hc
expression by mTORC1 has been described in glomerular epithe-
lial cells: in glomerulonephritis conditions, mTORC1 integrates
signals from inflammatory cytokines stimulating LAT2 translo-
cation to plasma membrane (Kurayama et al., 2011). Increased
surface LAT2 expression by DHT, via EGF receptor involving
the ERK1/2 cascade, has been described (Hamdi and Mutungi,
2011). The information above reported are summarized in
Table 1.
STRUCTURAL ASPECTS OF LAT1 AND LAT2
HATs seem to consist of a light chain (SLC7A5–11) with 12 puta-
tive TMD with the N- and C-terminals localized intracellularly
and an heavy chain with the C-terminal localized extracellu-
larly (Verrey et al., 2004; Costa et al., 2013). As stated above,
the 12 TMD of the light chains show considerable similarity
to the first 12 TMD of the CAT transporters. The heavy chain
4F2hc is a N-glycosylated protein (4 putative N-glycosylation
sites: N264,280,323,405) with one transmembrane domain. The
structure of the extracellular domain of human 4F2hc has been
solved by X-ray diffraction (Fort et al., 2007). On the contrary, the
structure of human LATs is not known, but Cys-scanning muta-
genesis showed that the Cys residue between TMD III and IV
is conserved being responsible of inter-subunit disulfide bridge
with the heavy chain. LATs show significant similarity to the argi-
nine/agmantine antiporter AdiC, to the broad-specificity amino
acid transporter ApcT and to the glutamate/GABA antiporter
from E. coli whose structures have been solved by X-ray crystal-
lography (Shaffer et al., 2009; Ma et al., 2012). A recent study
confirmed this hypothesis for LAT1 suggesting a translocation
mechanism in which the role of Na+ is mimicked by a pro-
ton with an alternating transport mechanism (Forrest et al.,
2011; Geier et al., 2013). The availability of this model allowed
screening and molecular docking of potential anti-tumor drugs,
revealing new substrates for LAT1 (Geier et al., 2013). Structural
studies on LAT2 have been conducted upon over-expression
of the heterodimer in P. pastoris with subsequent large scale
purification (Costa et al., 2013; Rosell et al., 2014). The study
shows, by different experimental approaches, that the extracellu-
lar domain of 4F2hc covers the surface of human LAT2 modeled
on the basis of AdiC transporter. The docking model fitted
the steric hindrance derived by cross-linking experiments and
highlighted that the Cys residue involved in the formation of
disulfide is the C154 between TMD III and IV. Interestingly,
the interaction mode described shed new light on the role of
4F2hc on the path cycle of LAT2: the strong interaction of the
heavy chain with a specific domain, named “hash domain,” of
LAT2 makes this part of the heterodimer the more static (close
to TMD 11 and 12), while the “boundle domain” including
helices 1, 2, 6, 7, and loops 7–8 is the one moving during
the transport cycle opening and closing the transporter (Rosell
et al., 2014). This mechanism might be shared also by the other
HATs.
Further structural features were already described for LAT1
and LAT2 transporters: potential casein kinase II-dependent
phosphorylation site(s), PKC phosphorylation motifs, tyrosine
kinase dependent phosphorylation sites (Prasad et al., 1999;
Segawa et al., 1999). The alignment of the rat and human
LAT2 sequences shows high percentage of identity (92%, not
shown). This data has been confirmed by the superimposi-
tion of the two structural model (RMSD 0.66) obtained by
using the structure of ADiC transporter as template (PDB
3OB6; Figure 6). Differently from the other glutamine trans-
porters, Scan-Prosite analysis predicts lack of glycosylation sites.
For these transporters the targeting to the membrane is guar-
anteed by their binding partner (Costa et al., 2013; Rosell
et al., 2014). This interaction is mediated by disulfide bridge
involving C154 for the human isoform and C155 for the rat
isoform exposed toward the extracellular side of the proteins
(Figure 6). Both the isoforms contain 11 Cys residues. No
metal binding motif has been found. On the opposite side the
human model contains 3 serine residues (S179, S337, S487),
putative PKC phosphorylation sites and a threonine residue
(T363), putative PKA phosphorylation site. These sites are
exposed toward the cytosolic side of the protein. The rat and
human proteins show nearly overlapping predicted structures
(Figure 6).
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FIGURE 6 | Homology models of LAT2 human and rat transporters. The
homology structural models of rat (Chaudhry et al.) and human (purple)
LAT2 were constructed as described in Figure 4 using as template the
structure of the arginine/agmantine antiporter AdiC from E. coli (PDB
3OB6). Superposition of the rat and human structural models was
performed by VMD 1.9.1. C154 of the human protein involved in disulfide
bridge with 4F2hc is highlighted in yellow; putative PKC and PKA
phosphorylation sites are highlighted in green. N- and C- terminals of rat
and human proteins are nearly coincident and highlighted by single N and C.
SLC7A6: Y+LAT2
Together with LAT1 and LAT2, this transporter belongs to the
SLC7 family. The gene encoding the human isoform of y+LAT2
has been isolated in 1999 and annotated on the chromosome
16q22.1 (Pfeiffer et al., 1999). The protein is constituted by
515 amino acids and is mainly expressed in brain, small intes-
tine, testis, parotids, heart, kidney, lung. y+LAT2 works as het-
erodimer with 4F2hc like the other members of SLC7 family.
It has been identified as arginine/glutamine exchanger: this role
would be particularly important in brain where the protein
might supply cells with important amino acids. Very interest-
ingly, the catalytic mechanism of this transporter is unique:
y+LAT2, indeed, mediates uptake of neutral amino acids in
a Na+-dependent fashion, while cationic amino acid transport
is Na+-independent (Table 1). The exchange occurs with a 1:1
stoichiometry. The antiport mechanism is expected to be elec-
troneutral because the positive charge of the cationic amino acid
is compensated for the Na+ ion accompanying the neutral amino
acid (Broer et al., 2000).
SLC7A15: ArpAT
The gene encoding this transporter has been annotated by in
silico approach. BLAST analysis identified on mouse genome a
region containing a putative ORF fulfilling the requirements of
a transporter belonging to SLC7 family: it has 64% similarity
with b0,+AT, 12 TMD domains, 2 putative N-glycosylation sites
present also in LAT1 and the conserved Cys residue involved in
disulfide with SLC3 member. This mouse transporter was then
cloned and functionally characterized in HeLa cells; its over-
expression in the presence of rBAT or 4F2hc increased neutral
amino acid uptake. The transporter mediates uptake of alanine,
serine, glutamine and cystine in Na+-and pH-independent man-
ner. Analogously to LATs, ArpAT showed trans-stimulation. This
transporter is expressed in intestine and, at much lower levels, in
brain. Themain physiological role played by ArpATmay be linked
to providing dopamine to the non-neuronal dopaminergic sys-
tem which regulates intestinal Na+ absorption (Fernandez et al.,
2005). The most intriguing finding concerning this transporter is
its evolutionary history: arpAT gene is, in fact, conserved in rat,
dog, and chicken while it has been silenced in humans and chim-
panzee. This suggests that its role became, along with primates
evolution, not essential. The group which identified the trans-
porter speculated that this may find explanation in the different
diet of primates compared to other vertebrates (Fernandez et al.,
2005).
SLC38: SNATs
GENES AND TISSUE LOCALIZATION
The SLC38 family belongs to the Amino acid Polyamine-organo
Cation family (APC family) and includes 11 membrane trans-
porters most of which are known tomediate the net uptake of glu-
tamine, alanine, asparagine, histidine, arginine, and some other
neutral amino acids in those tissues where they are expressed
(Hagglund et al., 2011; Schioth et al., 2013). The most acknowl-
edged transporters from this family are 6 proteins, originally clas-
sified as systems A and N and subsequently as SNATs or SATs and
SNs, respectively. In this more recent classification, the numbers
assigned to SNATs (SAT or SN) correspond to the identification
numbers of the SLC38members. The other five members are still
at early stage of characterization. SNAT1, 2, and 4 (SLC38A1, 2
and 4) correspond to the old systems A. System A was firstly iso-
lated in 1965 (Christensen et al., 1965) and was defined by the
inhibition with the amino acid analog MeAIB. In 2000 the three
transporters belonging to such family were identified and the cod-
ing genes annotated on chromosome 12. The proteins SNAT1 and
SNAT2 are 486 and 505 amino acids in length, respectively. The
system N includes SNAT3, 5, and 7 (SLC38A3, 5 and 7). SNAT3
gene was identified in 1999 and annotated on the chromosome
3p21.31 (Chaudhry et al., 1999) encoding a protein of 503 amino
acids. Then, SNAT5 gene was cloned in 2001 and annotated on
the chromosome Xp11.23 (Nakanishi et al., 2001) encoding a
protein of 471 amino acids. SNAT7 gene is localized on chromo-
some 16q21 and encodes a protein of 461 amino acids. According
to GeneBank, different transcripts exist for these three genes,
reported in Table 1. The tissue distribution of SNATs is wide
and specific for each member: SNAT1 and SNAT2 are ubiquitous
(Albers et al., 2001; Chaudhry et al., 2002); SNAT3 is expressed
in liver, skeletal muscle, kidney and pancreas (Chaudhry et al.,
1999); SNAT 5 is expressed in stomach, brain, liver, lung, small
intestine, spleen, colon and kidney (Nakanishi et al., 2001);
SNAT7 is ubiquitous (Hagglund et al., 2011). Regarding sub-
cellular localization, SNATs are mostly localized in the basolateral
membrane of absorptive epithelia (Schioth et al., 2013; Broer,
2014) (Figure 2). SNAT1 seems to be also localized in intracellular
organelles in GABAergic neurons (Solbu et al., 2010). In nervous
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system, SNAT1 and SNAT2 are expressed in GABAergic and glu-
tamatergic neurons (Solbu et al., 2010) while SNAT3 and SNAT5
are expressed in astrocytes (Chaudhry et al., 2002). In pancreas
SNAT2 is localized in the α-cell membranes while SNAT3 in the
β-cell ones. In kidney SNAT3 is localized on the basolateral mem-
branes of the S3 segment of proximal tubules. In intestine an
apical sub-cellular localization has been proposed for SNAT5.
SLC38 family comprises also other five additional members whose
function is still orphan. SLC38A6 (SNAT6) gene is localized on
the chromosome 14q23.1 and is expressed mainly in brain and
liver (Nakanishi et al., 2001). SLC38A8 (SNAT8) gene is localized
on the chromosome 16q23.3 and the protein has a distribution
similar to that of SNAT7. The transcripts of the other members
SLC38A9, SLC38A10 and SLC38A11 derive from genes anno-
tated on chromosome 5q11.1, 17q25.3 and 2q24.3 respectively
(Sundberg et al., 2008).
FUNCTION
SNAT1 and 2 show a broad substrate specificity with preference
for glutamine besides methionine, proline, serine, asparagine,
glycine and histidine, while SNAT 4 is not considered as glu-
tamine transporter (Schioth et al., 2013; Broer, 2014) and refs
herein). SNAT 7, which was characterized later than SNAT 3 and
5, recognizes also arginine as substrate. SNAT7, considered mem-
ber of system N, shows also characteristics of system A, such as
broad substrate specificity (Hagglund et al., 2011). The known
members of the SLC38 family work as co-transporters for Na+,
in which amino acid uptake is driven by the Na+ electrochem-
ical gradient, inwardly directed (Mackenzie and Erickson, 2004)
(Table 1). For system A members (SNAT1, 2) the uptake of glu-
tamine results to be electrogenic, since each transport cycle causes
a net movement of a positive charge with a stoichiometry 1:1. On
the contrary, the transporters belonging to system N are also able
to counter transport Na+ and H+ giving rise to an electroneu-
tral transport mechanism. SNAT3 and 5, but not SNAT7, have a
unique hallmark to tolerate substitution of Na+ with Li+ (Kilberg
and Christensen, 1980; Mackenzie et al., 2003; Hagglund et al.,
2011). All the known SLC38 transporters are activated by increas-
ing pH from 6 to 8 (Mackenzie and Erickson, 2004). In addition
to Na+ or H+ coupled transport, SNAT3 mediates uncoupled
ion movement across the membrane (Schneider et al., 2007).
Thus, protons and other cations can pass through the transporter
by substrate dependent mode, while other ion conductances are
substrate independent. Whether this uncoupled transport has a
physiological function it is still unclear as above described for
B0AT1. Interestingly, a single residue, N76, is critical for coupled
and uncoupled ion flows in the glutamine transporter SNAT3
(Broer, 2009). Moreover, it has been reported that a mutation of
residue T380 affects the ability of Li+ to replace Na+ (Chaudhry
et al., 2001).
Under a physiological point of view, SNATs play different
role according to their localization (Figure 2). In nervous tissue,
members of system a take up glutamine released by members
of system N giving rise to the glutamine/glutamate cycle in
neurons. In astrocytes, glutamine is synthesized via glutamine
synthetase, using glutamate released by synapses and taken up via
EAAT1 (Glutamate transporter SLC1A3) or EAAT2 (Glutamate
transporter SLC1A2) (Schioth et al., 2013). Another example
of concerted action among SNATs occurs in pancreas among
alpha and beta-cells. At low plasmatic glutamine concentrations,
SNAT3 releases glutamine supplying substrate for SNAT2, stim-
ulating glucagon secretion. In the opposite condition, in the
presence of high glutamine concentrations, differently by what
above described, SNAT3 will accumulate glutamine which is then
converted to glutamate. This reaction provides intermediate for
TCA cycle, producing ATP that, similarly to what occurs in the
presence of glucose accumulated in the β-cells via GLUT2, will
inhibit KC potassium channels causing depolarization. This event
facilitates fusion of insulin containing secretory granules with the
plasma membrane (Jenstad and Chaudhry, 2013). Thus, SNAT3
which catalyzes both glutamine uptake and efflux can be con-
sidered a sensor of the nutritional state of the cell. However,
glutamine affinity at the intracellular face is still not known, due
to the difficulty in accessing the intracellular space in experi-
ments performed with intact cells. In kidney SNAT3 contributes
to glutamine absorption from the circulation; this is involved in
regulation of acid-base homeostasis (Busque and Wagner, 2009).
In liver SNAT1, SNAT2, SNAT3, and SNAT5 contribute to net
import of amino acids, particularly alanine and glutamine reg-
ulating gluconeogenesis and giving rise to the glutamine/alanine
cycle between liver and muscle (Kondou et al., 2013). In intes-
tine, where glutamine uptake from lumen is mediated by B0AT1
(Figure 2), transporters from system A have been proposed as the
main responsible of glutamine transfer to blood (Broer, 2008).
Interestingly, in this body district SNAT5 would be involved
in glutamine metabolism in crypts cells, even though further
investigations are needed (Saha et al., 2012).
The functional and kinetic characterizations described in the
cited papers, have been conducted in cell systems; so far, no exam-
ple of over-expression and reconstitution in proteoliposomes of
SNAT members is available. Thus, given their complex interplay,
some aspects are still unknown.
REGULATORY ASPECTS
The regulation of SNAT expression is a complex issue, not com-
pletely solved; the available information have been included in
Table 1. SNAT1 expression is stimulated by PKA (Ogura et al.,
2007). For SNAT2, a regulation by amino acid deprivation has
been described and the mechanism linked to the presence in the
first intron of a amino acid response element (AARE) acting as
enhancer (Palii et al., 2004). Moreover, in liver SNAT2 is up-
regulated by glucagon (Ortiz et al., 2011). For SNAT3 a regulation
by PKC has been reported and linked to the glutamate/GABA-
glutamine of the central nervous system. Derangement of SNAT3
regulation may cause pathological states both in the central
nervous system and in peripheral organs (Nissen-Meyer and
Chaudhry, 2013). Moreover, SNAT5 expression has been found
regulated by c-myc in cancer cells (Deberardinis et al., 2007).
STRUCTURAL ASPECTS
The structure of the SLC38 members is characterized by a 5+5
inverted repeat fold typical of the bacterial LeuT (Broer, 2014).
Recently, by bioinformatics and labeling experiments, the homol-
ogy model of SNAT4 (built on LeuT and AdiC) has been validated
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(Shi et al., 2011). In this model the N- and C-terminals of the
protein are extracellular, as well as three loops containing two N-
glycosylation sites (N260 and N264). Interestingly, a disulphide
bridge linking C249 and C321 is essential for SNAT4 function,
which, however, is not a glutamine transporter. (Padmanabhan
Iyer et al., 2013). The structural model of SNAT7 has been built as
a representative of the SLC38 glutamine transporters, given that it
was the last characterized and, hence, an homology model was
not yet built (Figure 7). Interestingly, the alignment of SNAT7
with the other SLC38 members shows the lowest percentage of
identity from 19 to 21% (not shown). In addition, SNAT7 has
unique properties resembling those of both system A and N.
Differently by SLC1 and SLC6 transporters, homology models
built for human and rat SNAT7 proteins by Modeler do not have
the same fidelity of the others due to the low sequence simi-
larity to the available crystallized bacterial homologs (AdiC and
ApcT). SNAT2 model was already built on the basis of LeuT
crystal structure (Zhang et al., 2009). SNAT7 has the same topol-
ogy of the homology model previously described for SNAT4 (Shi
et al., 2011) with extracellular C- and N- terminals. Differently
by SNAT4 no N-glycosylation sites have been predicted by bioin-
formatics for the human and rat SNAT7 proteins. Concerning
the phosphorylation sites, a PKC binding site (T174) and a PKA
binding site (T179) have been found in the human isoform. The
same phosphorylation sites have been found in rat shifted of one
residue.
THE MITOCHONDRIAL GLUTAMINE TRANSPORTER
A mystery in the glutamine transporter ensemble is still repre-
sented by the mitochondrial member. This transporter should
FIGURE 7 | Homology models of SNAT7 human and rat transporters.
The homology structural models of rat (purple) and human (Chaudhry et al.)
SNAT7 were constructed as described in Figure 6. Superposition of the rat
and human structural models was performed by VMD 1.9.1. Putative PKC
and PKA phosphorylation sites are highlighted in green. N- and C- terminals
of rat and human proteins are nearly coincident and highlighted by single N
and C.
be essential in metabolism since release of ammonia by glu-
tamine deriving from extra hepatic tissues, should occur inside
the mitochondrial matrix, where the ubiquitous form of glu-
taminase, i.e., derived from GLS1 gene, is localized (Figure 2).
Glutaminase deriving from GLS1 gene exists in two splicing vari-
ants, both localized in mitochondria (Katt and Cerione, 2014).
Interestingly and in line with the role of glutamine in cancer
cell metabolism (see Section “Glutamine transporters in human
pathology”), the GLS1expression is altered in cancer. This has
been linked with suppression of miRNA23a and b via both c-
myc and NFkB pathways (Gao et al., 2009; Rathore et al., 2012).
Indeed, the metabolic flux of ammonia has been well demon-
strated to finish in mitochondria also on the basis of a recent
work on pancreatic cancer cells, in which glutamine transfer
to mitochondria, via transporters, is hypothesized due to the
impairment of the cell growth when GLS1 is knocked down (Son
et al., 2013). In spite of the great importance of the mitochon-
drial glutamine transporter, only preliminary evidences on this
transport function were provided by old studies in intact mito-
chondria (Sastrasinh and Sastrasinh, 1989) and then the protein
responsible for this function was isolated and purified frommito-
chondrial extracts (Indiveri et al., 1998). Afterwards no other
advances on the identification of the protein and/or the gene
encoding the mitochondrial glutamine transporter have been
achieved. Interestingly, the mentioned glutamine transporter has
a higher apparent molecular mass, 41.5 kDa, than canonical mito-
chondrial carriers, i.e., 28–34 kDa. Therefore, the mitochondrial
glutamine transporter may or not belong to the mitochondrial
carrier family. Indeed, a mitochondrial carrier with a longer N-
terminal extension has been described (Palmieri, 2008) as well
as a mitochondrial transporter which does not belong to the
mitochondrial carrier family (Herzig et al., 2012).
GLUTAMINE TRANSPORTERS IN HUMAN PATHOLOGY
The involvement of glutamine transporters in human pathology
has been investigated and, with the only exception of the autoso-
mal recessive disorder Hartnup disease, the only pathology linked
to alteration of glutamine homeostasis, is cancer. Glutamine plays
pivotal role in cell proliferation which requires nutrients, energy
and increased biosynthetic activity leading to overall metabolic
changes. In this scenario, cells shift to high glycolysis rate, lac-
tate production and increased lipid biosynthesis. These pathways
have been firstly described in lymphocytes which represent an
useful model for studying cell proliferation (Deberardinis et al.,
2008; Vander Heiden, 2011). Interestingly, a similar metabolic
shift is a typical feature of cancer cells that need glucose and glu-
tamine to sustain the high rate of proliferation (Fuchs and Bode,
2005; Ganapathy et al., 2009; Chen and Russo, 2012; Daye and
Wellen, 2012; Son et al., 2013). Differential expression of specific
genes, in particular those coding for plasma membrane trans-
porters, allows increased uptake of the two nutrients. Normal
proliferating cells need to integrate signals coming from extracel-
lular growth factors, while cancer cells have increased autonomy.
The main metabolic changes occurring in cancer are collec-
tively known as Warburg effect (Ganapathy et al., 2009; Vander
Heiden et al., 2009; Dang, 2010; Ohh, 2012). This phenomenon
relies, besides increased glucose utilization, also on glutamine,
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canonically classified as “non-essential” amino acid that gives
rise to a truncated form of TCA, terminating with malate and
producing ATP at the substrate level (Figure 8). Malate is con-
verted to pyruvate and lactate allowing cancer cells to produce
ATP and NADPH necessary for anabolic processes (Figure 8).
Lactate is exported by MCTs which are also over-expressed in
tumors (Halestrap, 2013). Moreover, glutamine sustains cytoso-
lic citrate synthesis via IDH1 and lipogenesis (Metallo, 2012)
(Figure 8).
Therefore, it is not surprising that plasma membrane trans-
porters responsible of glutamine disposition are altered in sev-
eral human cancers. Among the transporters described in the
above Sections, LAT1 (SLC7A5) and ASCT2 (SLC1A5) are those
for which over expression in several tumors has been docu-
mented since 2005 (Fuchs and Bode, 2005). Specific examples
of human cancers are listed in Table 2. In nearly all cases,
over-expression of ASCT2 and LAT1 correlates with high grade
of malignancies of these tumors. However, the role of ASCT2
in providing glutamine to cells (Nicklin et al., 2009) must
be revisited in view of the well assessed obligatory antiport
and functional asymmetry (Pingitore et al., 2013). Energy sup-
ply from glutamine will not result from the entire glutamine
molecule (five carbon atoms) but from the difference between
the carbon atoms taken up as glutamine and those exported as
smaller amino acids such as serine and threonine (Figure 8).
This difference accounts for one or two carbon atoms which
are oxidized in the truncated TCA. The membrane transporters
SNAT1, SNAT3, and SNAT 5 have been also shown over-
expressed in some cancers (Table 2), to accomplish glutamine
supply; these findings opened perspectives on SNATs as phar-
macological targets, even though lack of suitable experimental
tool made this issue still difficult to approach. Noteworthy, the
low affinity glutamine transporter ATB0,+ is also up-regulated
in some tumors, even though this is linked with its pri-
mary function of providing arginine to cells (Gupta et al.,
2005).
Only one inherited pathology, named Hartnup disorder
(OMIM 234500), is clearly associated to a glutamine transporter,
i.e., B0 AT1. So far, 21 mutations have been described as causative
of such pathology onset. This metabolic syndrome is complex
and characterized by pellagra-like rash, cerebellar ataxia, emo-
tional instability and strong aminoaciduria. Even though B0 AT1
is responsible also of glutamine absorption and reabsorption, the
amino acids for which underlies its role in Hartnup disease are
mainly histidine and tryptophan (Broer, 2009). The dramatic loss
of such amino acids in urine is responsible of decreased sero-
tonin and melatonin syntheses, explaining the neurological and
skin problems, respectively.
FIGURE 8 | Network of transporters involved in cancer metabolic
switch. In cell membrane (red), ASCT2 and LAT1: glutamine plasma
membrane transporters; MCT: Monocarboxylate Transporter. In cytosol
(upper part of the figure), Gln: glutamine, Glu: glutamate, αKG: α
Ketoglutarate, ICIT: isocitrate, IDH1: Isocitrate dehydrognase 1 and
simplification of reactions to fatty acid synthesis; (lower part of the
figure) Mal: Malate, Lac: lactate and simplification of glycolysis with the
end product pyruvate (Pyr). In the Inner Mitochondrial Membrane,
putative glutamine transporter (?). In mitochondrial matrix, TCA
(Tricarboxylic Acid Cycle) with enzymes, GLS: Glutaminase, GDH:
Glutamate dehyfrogenase, ALT: Alanine Amino Transferase. AA: Amino
Acid. Dotted arrows indicate metabolic pathways depressed in cancers.
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Table 2 | SNATs, ASCT2, and LAT1 associated cancers.
Cancer type SLC38 (SNATs) SLC1A5 (ASCT2) SLC7A5 (LAT1)
Prostate cancer Okudaira et al., 2011 Busque et al., 2009; Li et al., 2013 Patel et al., 2013; Segawa et al., 2013
Colorectal cancer Witte et al., 2002 Ebara et al., 2010
Hepato Cell Carcinoma Kondoh et al., 2007 Bode et al., 2002; Fuchs et al., 2004 Li et al., 2013
Lung cancer Hassanein et al., 2013; Shimizu et al., 2014 Kaira et al., 2010; Imai et al., 2010
Breast cancer Wang et al., 2013 Kim et al., 2012 Furuya et al., 2012
Neuroblastoma and glioma Sidoryk et al., 2004 Wasa et al., 2002; Dolinska et al., 2003
Endometrioid carcinoma Watanabe et al., 2014
Ovarian Cancer Kaji et al., 2010
Renal Cell Carcinoma Betsunoh et al., 2013
Pancreatic andbiliary tract cancer Yanagisawa et al., 2012; Kaira et al., 2013
Gastric cancer Shi et al., 2013
Pleural Mesothelioma Kaira et al., 2011
List of cancer tissues in which SNATs, ASCT2 and/or LAT1 have been found over-expressed with related references.
TOXICOLOGY AND PHARMACOLOGY: ASCT2 AND LAT1 AND
DRUG INTERACTIONS
The results above described highlighted the importance of glu-
tamine membrane transporters in metabolic changes for cancer
development and/or progression. This shed light, since years, on
the pharmacological relevance of ASCT2 and LAT1 which became
hot targets of drug discovery. Moreover, the pivotal role played
by plasma membrane transporters in interaction with drugs is
becoming more and more important and several evidences link
these proteins to drug disposition among tissues and among dif-
ferent subcellular compartments (Giacomini et al., 2010; Pochini
et al., 2013; Scalise et al., 2013). The challenge of advancing in this
research field is represented by the possibility of designing good
inhibitors able to specifically target the protein of interest. These
studies started since some years and different groups reported
attempts of designing and identifying specific inhibitors of ASCT2
(Grewer and Grabsch, 2004; Albers et al., 2012) and LAT1 (Geier
et al., 2013). The design of specific and selective molecules
requires the knowledge of the tridimensional structures of the tar-
get. However, so far, nearly no structures of human secondary
membrane transporters have been solved due to the difficulty
in handling them and to the lack of methodologies for over-
expressing and folding. Only very recently the human isoform
of GLUT1 transporter has been solved by X-ray diffraction, even
though in an inactive form obtained by site-directed mutagenesis
(Deng et al., 2014). The possibility to identify new compounds
is therefore mostly based on integration between experimental
procedures and bioinformatics, through homology modeling and
molecular docking. The homology model structures previously
obtained (Oppedisano et al., 2010, 2011; Pingitore et al., 2013;
Pochini et al., 2014) and now improved (Figures 4, 5) have been
used for several toxicological studies (see below). In the mean-
time, a lot of efforts have been made to obtain human isoforms
of ASCT2 and LAT1 by over-expressing them in heterologous
systems, following the work flow depicted in Figure 3. These pro-
cedures are useful to recover high yield of purified protein needed
for both functional and structural studies. The two amino acid
transporters hASCT2 and hLAT1/CD98 have been recently cloned
and over-expressed in the yeast P. pastoris and in the bacterium
E. coli, respectively (Galluccio et al., 2013; Pingitore et al., 2013).
Even though the two proteins are both glutamine transporters, a
common strategy could not be applied. This was not surprising
given the experience already acquired with the three members of
OCTN family (Indiveri et al., 2013).
The availability of these proteins in purified and in native form
opens the possibility of obtaining X-ray structure for better defin-
ing or validating the already available homology models depicted
in Figures 4, 6. Combining the over-expression systems and the
procedures of proteoliposomes reconstitution, it will be soon pos-
sible to develop assays for high throughput screening of chemical
compounds for drug discovery and design before animal experi-
mentation (Pochini et al., 2013; Scalise et al., 2013), as depicted
in the work flow of Figure 3. These kind of studies can be per-
formed also in cell systems stably or transiently over-expressing
the protein of interest; however, given the pleiotropy of glutamine
and the broad substrate specificity of amino acid transporters, a
strategy allowing the study of isolated proteins in artificial mem-
branes is indispensable as suggested by several authors (McGivan
and Bungard, 2007; Scalise et al., 2013; Schioth et al., 2013).
By mean of proteoliposome reconstitution, some studies evalu-
ating toxicological aspects of glutamine transporters have been
already performed on the rat protein, extracted in native form
from kidney, being the human isoforms not available at that
time (see above in ASCT2 and B0AT1 Sections). Such studies
gave the possibility of confirming also structure/function rela-
tionships speculated on the basis of homology models presented
in Figures 4, 5. The works moved from the observation that some
amino acid residues, such as Cys, increased their relative concen-
trations during protein evolution (Jordan et al., 2005). This makes
Cys a potential target of different SH-reactive molecules; note-
worthy the glutamine transporters dealt with the present review
harbor several Cys residues. ASCT2 and B0AT1, indeed, were
shown to be inhibited by several SH-reagents. Under a toxico-
logical point of view, an interesting class of SH-reagents are the
mercurial compounds. These molecules are potent environmen-
tal contaminants coming from industries with high toxicity for
humans and in general for mammals since they enter the food
chain as bio-product of bacterial metabolism (Rooney, 2007).
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A first work has been performed with ASCT2; this protein showed
to be potently inhibited by HgCl2, methyl-mercury and other
heavy metals (Oppedisano et al., 2010). The compounds inter-
act very probably with a CXXC metal binding motif located at
the end of the large hydrophilic loop of the transporter in a
basin surrounded by hydrophobic residues (Figure 4A). The IC50
measured for mercury compounds are in the range of toxicity
threshold. These results explain at the molecular level the toxic
effect of methyl-mercury in brain (Boado et al., 2005). A large
scale screening of drugs has been performed on ASCT2 in the
same system (Oppedisano et al., 2012). In particular, potential
anti-tumor drugs, dithiazoles, where designed specifically for rat
ASCT2 and tested to identify the structural features of the most
potent ones; the study revealed again that the CXXC motif is
involved in covalent interaction with those drugs.
Another study in the proteoliposomes system has been con-
ducted on B0AT1 extracted from rat kidney. Even though the
structure of rat B0AT1 is not related with that of rat ASCT2,
the transporters share the common feature of carrying CXXC
metal binding motifs. In the case of B0AT1, the CXXC motif
has been localized far from the putative binding site, correlat-
ing with the non-competitive inhibition by mercury compounds
(Oppedisano et al., 2011) (Figure 5). B0AT1 contains, in addi-
tion, a CXXXC motif which has been described previously as
target of metals such as Cu2+, Pb2+, Hg2+, Cd2+, and Zn2+
(Abajian and Rosenzweig, 2006; Tonazzi and Indiveri, 2011). This
seconds second motif might explain the effect exerted by the
prototype of mercury agent, mersalyl. In this case, in fact, sub-
strate protection of the inhibition was found (Oppedisano et al.,
2011). Interestingly, anti-oxidants are able to reverse the inhibi-
tion in both ASCT2 and B0AT1 proteins (Scalise et al., 2013).
Very recently, a large scale screening of drugs has been performed
on rat B0AT1 describing a specific inhibitory effect exerted by
the common anti-inflammatory drug nimesulide (Pochini et al.,
2014). Experimental data were supported by molecular docking
of nimesulide on the rat B0AT1 showing that the site of drug inter-
action corresponds to that for antidepressants in SERT and GABA
transporters (Krishnamurthy and Gouaux, 2012; Penmatsa et al.,
2013). This feature, together with the high degree of identity
between rat and human, makes reconstituted B0AT1 an impor-
tant model for pharmacological and toxicological screening with
applicability in humans. On the contrary, among the glutamine
transporters described in this review, ASCT2 has the unique fea-
ture of being locally different between rat and human orthologs,
making the availability of the human over-expressed transporter
essential for applications in human health.
CONCLUSION
Glutamine is a “conditionally essential” amino acid which home-
ostasis is maintained owing to the different mode of trans-
port performed by several membrane transporters. Thus, on the
one hand, concentrative transporters allow glutamine absorption
from diet in intestine and reabsorption from urine in kidney.
On the other hand, both co-transporters and antiporters allow
delivery of glutamine in all the tissues and equilibration with
other amino acids. The redundancy of transporters with over-
lapping functional properties is very probably related to the need
of avoiding derangements from homeostasis even in case of mal-
functioning of one transporter. The lack of known defects of genes
encoding these transporters, with very few exception, is in some
instances an evidence that derangements of glutamine homeosta-
sis is incompatible with life. Notwithstanding all the transporters
dealt with share specificity for glutamine, they display different
tridimensional structures. This is in line with their classification
in different protein families; however, within the same family, the
orthologs are very conserved from rat to human. The only excep-
tion is represented by ASCT2 (SLC1A5) whichmay be related with
some specific signaling role of the transporter arisen later in evo-
lution. While the function of several transporters has been widely
described, no structures are available and the molecular mech-
anisms of regulation are still not completely solved. Thus, a lot
remains to be done for a comprehensive knowledge of glutamine
fluxes through tissues. This is very important not only for the bio-
chemical knowledge of the glutamine homeostasis but also, and
more importantly, for the involvement of this special amino acid
in the hottest topic of human health: cancer biology.
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